Human Molecular Genetics Advance Access published online on December 1, 2005
Human Molecular Genetics, doi:10.1093/hmg/ddi439
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 GSF-National Research Center for Environment and Health, Institute of Human Genetics, Munich-Neuherberg, Germany
* To whom correspondence should be addressed. Mutations in the leucine-rich repeat kinase 2 gene (LRRK2) have been recently identified in families with autosomal dominant late-onset Parkinson disease (PD). The LRRK2 protein consists of multiple domains and belongs to the Roco family, a novel group of the Ras/GTPase superfamily. Besides the GTPase (Roc) domain it contains a predicted kinase domain, with homology to MAP kinase kinase kinases (MAPKKK). Using cell fractionation and immunofluorescence microscopy we show that LRRK2 is localised in the cytoplasm and is associated with cellular membrane structures. The purified LRRK2 protein demonstrates autokinase activity. The disease associated I2020T mutant shows a significant increase in autophosphorylation of about 40% in comparison to wild-type protein in vitro. This suggests that the pathology of PD caused by the I2020T mutation is associated with an increase rather than a loss in LRRK2 kinase activity.
Received September 17, 2005
Accepted November 25, 2005
Article
The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity
Christian Johannes Gloeckner 1,
Norbert Kinkl 2,
Annette Schumacher 1,
Ralf J. Braun 1,
Eric O'Neill 3,
Thomas Meitinger 2,
Walter Kolch 3,
Holger Prokisch 2,
and
Marius Ueffing 4 *
2 GSF-National Research Center for Environment and Health, Institute of Human Genetics, Munich-Neuherberg, Germany; Institute of Human Genetics, Technical University Munich, Munich, Germany
3 The Beatson Institute for Cancer Research, Glasgow, UK
4 GSF-National Research Center for Environment and Health, Institute of Human Genetics, Ingolstaedter Landstr. 1, 85764, Munich-Neuherberg, Germany; Institute of Human Genetics, Technical University Munich, Munich, Germany
Marius Ueffing, E-mail: marius.ueffing{at}gsf.de
![]()
Abstract ![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
H. S. Ko, R. Bailey, W. W. Smith, Z. Liu, J.-H. Shin, Y.-I. Lee, Y.-J. Zhang, H. Jiang, C. A. Ross, D. J. Moore, et al. CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity PNAS, February 24, 2009; 106(8): 2897 - 2902. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. C.-Y. Ho, H. J. Rideout, E. Ribe, C. M. Troy, and W. T. Dauer The Parkinson Disease Protein Leucine-Rich Repeat Kinase 2 Transduces Death Signals via Fas-Associated Protein with Death Domain and Caspase-8 in a Cellular Model of Neurodegeneration J. Neurosci., January 28, 2009; 29(4): 1011 - 1016. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Marin, W. N. van Egmond, and P. J. M. van Haastert The Roco protein family: a functional perspective FASEB J, September 1, 2008; 22(9): 3103 - 3110. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Mizuno, N. Hattori, S.-i. Kubo, S. Sato, K. Nishioka, T. Hatano, H. Tomiyama, M. Funayama, Y. Machida, and H. Mochizuki Progress in the pathogenesis and genetics of Parkinson's disease Phil Trans R Soc B, June 27, 2008; 363(1500): 2215 - 2227. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Greggio, I. Zambrano, A. Kaganovich, A. Beilina, J.-M. Taymans, V. Daniels, P. Lewis, S. Jain, J. Ding, A. Syed, et al. The Parkinson Disease-associated Leucine-rich Repeat Kinase 2 (LRRK2) Is a Dimer That Undergoes Intramolecular Autophosphorylation J. Biol. Chem., June 13, 2008; 283(24): 16906 - 16914. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Weiss ROCO Kinase Activity Is Controlled by Internal GTPase Function Sci. Signal., June 10, 2008; 1(23): pe27 - pe27. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Wang, C. Xie, E. Greggio, L. Parisiadou, H. Shim, L. Sun, J. Chandran, X. Lin, C. Lai, W.-J. Yang, et al. The Chaperone Activity of Heat Shock Protein 90 Is Critical for Maintaining the Stability of Leucine-Rich Repeat Kinase 2 J. Neurosci., March 26, 2008; 28(13): 3384 - 3391. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Liu, X. Wang, Y. Yu, X. Li, T. Wang, H. Jiang, Q. Ren, Y. Jiao, A. Sawa, T. Moran, et al. A Drosophila model for LRRK2-linked parkinsonism PNAS, February 19, 2008; 105(7): 2693 - 2698. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Deng, P. A. Lewis, E. Greggio, E. Sluch, A. Beilina, and M. R. Cookson Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase PNAS, February 5, 2008; 105(5): 1499 - 1504. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Chen, M. Rzhetskaya, T. Kareva, R. Bland, M. J. During, A. W. Tank, N. Kholodilov, and R. E. Burke Antiapoptotic and Trophic Effects of Dominant-Negative Forms of Dual Leucine Zipper Kinase in Dopamine Neurons of the Substantia Nigra In Vivo J. Neurosci., January 16, 2008; 28(3): 672 - 680. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Klein and M. G. Schlossmacher Parkinson disease, 10 years after its genetic revolution: Multiple clues to a complex disorder Neurology, November 27, 2007; 69(22): 2093 - 2104. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Cookson, W. Dauer, T. Dawson, E. A. Fon, M. Guo, and J. Shen The Roles of Kinases in Familial Parkinson's Disease J. Neurosci., October 31, 2007; 27(44): 11865 - 11868. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Thomas and M. F. Beal Parkinson's disease Hum. Mol. Genet., October 15, 2007; 16(R2): R183 - R194. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Luzon-Toro, E. R. de la Torre, A. Delgado, J. Perez-Tur, and S. Hilfiker Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation Hum. Mol. Genet., September 1, 2007; 16(17): 2031 - 2039. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Iaccarino, C. Crosio, C. Vitale, G. Sanna, M. T. Carri, and P. Barone Apoptotic mechanisms in mutant LRRK2-mediated cell death Hum. Mol. Genet., June 1, 2007; 16(11): 1319 - 1326. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Mandemakers, V. A. Morais, and B. De Strooper A cell biological perspective on mitochondrial dysfunction in Parkinson disease and other neurodegenerative diseases J. Cell Sci., May 15, 2007; 120(10): 1707 - 1716. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Hatano, S.-i. Kubo, S. Imai, M. Maeda, K. Ishikawa, Y. Mizuno, and N. Hattori Leucine-rich repeat kinase 2 associates with lipid rafts Hum. Mol. Genet., March 15, 2007; 16(6): 678 - 690. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Lesage, S. Janin, E. Lohmann, A.-L. Leutenegger, L. Leclere, F. Viallet, P. Pollak, F. Durif, S. Thobois, V. Layet, et al. LRRK2 Exon 41 Mutations in Sporadic Parkinson Disease in Europeans Arch Neurol, March 1, 2007; 64(3): 425 - 430. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. B. West, D. J. Moore, C. Choi, S. A. Andrabi, X. Li, D. Dikeman, S. Biskup, Z. Zhang, K.-L. Lim, V. L. Dawson, et al. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity Hum. Mol. Genet., January 15, 2007; 16(2): 223 - 232. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Marin The Parkinson Disease Gene LRRK2: Evolutionary and Structural Insights Mol. Biol. Evol., December 1, 2006; 23(12): 2423 - 2433. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. H. V. Schapira The Importance of LRRK2 Mutations in Parkinson Disease. Arch Neurol, September 1, 2006; 63(9): 1225 - 1228. [Full Text] [PDF] |
||||
![]() |
S. Papapetropoulos, C. Singer, O. A. Ross, M. Toft, J. L. Johnson, M. J. Farrer, and D. C. Mash Clinical Heterogeneity of the LRRK2 G2019S Mutation. Arch Neurol, September 1, 2006; 63(9): 1242 - 1246. [Abstract] [Full Text] [PDF] |
||||










